RecruitingNCT06675851

Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People

This study is recruiting. It focuses on depression and currently lists participation information in Austria.

DepressionDrugFrom 18 Years to 65 Years

Need help deciding?

Ask HopeStage to review this study with me

Study reference: NCT06675851. HopeStage can help you review the study, but cannot decide medical eligibility.

In plain English

Key information made simple

This study is comparing WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline with Healthy Controls without antidepressant intake for people with depression. Participants receive WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline or Healthy Controls without antidepressant intake and complete study visits and assessments. Some participants may receive Healthy Controls without antidepressant intake instead of the study treatment, and direct benefit is not guaranteed.

What to expect

Your next step

The official record suggests in-person participation through a university, with sites including Medical University of Vienna. Participation appears to involve assessments along with scans or samples to help researchers understand patterns more clearly. The main fit is usually matching the main diagnosis and being able to follow the planned visits or tasks, while common reasons not to take part include major medical issues that could make participation unsuitable. This is a later-stage study, which usually means the approach is being followed in broader real-world use.

Before joining

Questions to ask before joining

What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?

Study clarity

Things to check before joining

Study start dateStarted: December 1, 2022

Time commitment: multiple visits or assessments
Study phase: Not available
Enrollment: Not available
Recruitment status: Recruiting
Sponsor: Medical University of Vienna
Sponsor type: University
Main activity: medication or study treatment
Intervention: Not available
Source: Official registry link

Want help reviewing this study?

Public study data

Key study information

Official title: Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People
Condition: Depression
Study status: Recruiting
Sponsor / lead affiliation: Medical University of Vienna
Location / country: Austria
Registry: ClinicalTrials.gov
External trial ID: NCT06675851

Why this study may matter

This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.

In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Austria.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Official title: Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People
Source: ClinicalTrials.gov
Official registry link: Open official registry
External trial ID: NCT06675851

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People?

This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Medical University of Vienna. Based on the sponsor name or official registry information, it appears to be a university. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve medication or study treatment, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me